Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Transfusion-Dependent Low/Intermediate-1 Risk MDS with Del 5q
NCT00179621Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2005
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of lenalidomide in myelodysplastic syndrome (MDS) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days) up to 52 weeks. Started Jul 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00179621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179621.